Zentalis Pharmaceuticals Llc (ZNTL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.11 (+0.97%), Market cap $0.29B, 52-week low–high $1.16 ~ $6.61.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 20
Financial statements, price targets, institutional (13F) holdings and related news for Zentalis Pharmaceuticals Llc are updated in real time on BlackAll Trade.
Zentalis Pharmaceuticals Llc trades at $3.11 (+0.97%). Real-time quotes and charts are available on BlackAll Trade.
Zentalis Pharmaceuticals Llc has a market cap of about $0.29B.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.